OBJECTIVES:  In the context of reimbursement inclusion decisions on pharmaceuticals, several aspects are taken into account. One of these is the budget impact analysis (BIA), which estimates the financial consequences of the social insurance inclusion of new therapies within a specific health-care system context. The aim of our poster was to make recommendations related to the Hungarian pharmacoeconomic guideline based on an international review of BIA. METHODS:  The methodology of this study included a systematic review and analysis of the relevant national and international literature as well as publicly available materials of HTA agencies. RESULTS:  Recommendations regarding BIA appear typically as part of pharmacoeconomic guidelines. Nevertheless, their content, extent and structure show notable differences. As a result of the research, we identified 12 domains, 6 of which play a major role in the Hungarian guideline. In the case of the other 6 domains, the Hungarian guideline needs to be developed further (model design, consistency with the cost effectiveness analysis, compared scenarios, estimation of the affected population, reduction of uncertainty, validation). CONCLUSIONS:  It is recommended that development proposals regarding the national guideline are to be pasted in the current structure. Furthermore, it is worth considering as to what type of supporting materials might prove helpful in the preparation/appraisal of the BIA.